Abstract:Background: Activating Transcription Factor 4 (ATF4) expression exhibits differential patterns across different types of tumors. Besides, the pathogenesis of breast cancer is complex, and the exact relationship between ATF4 and ATF4 remains uncertain. Methods: The analysis of ATF4 expression was conducted by utilizing The Cancer Genome Atlas (TCGA) pan-cancer data, while the gene expression profile of breast cancer was checked by the comprehensive database-Gene Expression Omnibus database. In order to gain a more comprehensive understanding of the specific cell types that exhibit ATF4 expression within the microenvironment of breast cancer, we conducted a single-cell analysis of ATF4 using two distinct datasets of human breast cancer (GSE114717 and GSE11088, respectively). The spatial distribution of ATF4 within a tissue was demonstrated based on datasets obtained from the Human Protein Atlas (HPA) and SpatialDB. The clinical prognostic significance of ATF4 was assessed by analyzing clinical survival data obtained from TCGA, GSE4830, and GSE25055 datasets. We used the R package clusterProfiler to carry out an enrichment analysis of ATF4. We assessed how ATF4 impacts the growth and movement of breast cancer cell lines. We manipulated ATF4 levels using plasmid transfection techniques. Results: The expression of ATF4 was found to be suboptimal and demonstrated a significant correlation with enhanced disease-specific survival (p = 0.012) and overall survival (p = 0.032) in breast cancer as well as other malignancies. We conducted an analysis to investigate the interaction between the infiltration level of immune cells and the expression of ATF4, using samples obtained from TCGA with known immune cell infiltration scores. Furthermore, a notable positive correlation exists between the elevated expression of ATF4 and immune-related genomes, specifically those associated with chemokine as well as immunity. Subsequent examination revealed a notable augmentation in the cytodifferentiation of T cells into regulatory T (Treg) cells within tissues exhibiting elevated levels of ATF4 expression. ATF4 exhibits notable upregulation in the MDA-MB-231 cell, thereby exerting a substantial impact on cell proliferation and migration upon its knockdown. Conversely, the overexpression of ATF4 in the MCF7 Luminal A breast cancer cell line can also modulate cellular function. Conclusions: Our study suggests that ATF4 helps T cells differentiate into Treg cells in breast cancer. ATF4 can represent a clinically useful biomarker to predict the overall survival rate, especially in patients with different subtypes of breast cancer. Provide certain guidance value for the development of targeted drugs or inhibitors targeting ATF4.

Activating transcription factor 4 in malignant tumors and drug resistance

ATF4/NUPR1 Axis Promotes Cancer Cell Survival and Mediates Immunosuppression in Clear Cell Renal Cell Carcinoma

Activating transcription factor 4: a regulator of stress response in human cancers

An Overview of Research Advances in Oncology Regarding the Transcription Factor ATF4

ATF4 promotes lung cancer cell proliferation and invasion partially through regulating Wnt/β-catenin signaling

ATF4 Regulates CCL2 Expression to Promote Endometrial Cancer Growth by Controlling Macrophage Infiltration

Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation

A Bioinformatic Analysis Found Low Expression and Clinical Significance of ATF4 in Breast Cancer

ATF4 in cellular stress, ferroptosis, and cancer

ATF family members as therapeutic targets in cancer: From mechanisms to pharmacological interventions

ATF1 promotes malignancy of lung adenocarcinoma cells through transcriptionally regulating ZNF143 expression

ATF4 inhibits tumor development and mediates p-GCN2/ASNS upregulation in colon cancer

CK1 stimulates ubiquitination-dependent proteasomal degradation of ATF4 to promote chemoresistance in gastric Cancer

The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression

TR4 Nuclear Receptor Enhances the Cisplatin Chemo-Sensitivity Via Altering the ATF3 Expression to Better Suppress HCC Cell Growth

TRAF4 mediates activation of TGF-β signaling and is a biomarker for oncogenesis in breast cancer

Transcription factor AP-4 promotes tumorigenic capability and activates the Wnt/β-catenin pathway in hepatocellular carcinoma

High ATF4 Expression Is Associated With Poor Prognosis, Amino Acid Metabolism, and Autophagy in Gastric Cancer

Activating Transcription Factor 4 is Critical for Proliferation and Survival in Primary Bone Marrow Stromal Cells and Calvarial Osteoblasts

The role of basic leucine zipper transcription factor E4BP4 in cancer: a review and update

The Oncogenic and Tumor Suppressor Activities of ATF-2